Precision medicine is an emerging approach for disease treatment where genes, the environment and lifestyle of each person is taken into account.
This rural telehealth consultation program named Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) was launched by the Department of Veterans Affairs in New Mexico in 2012. To begin with, this program was used for chronic liver disease. This consultation connected rural care teams to specialty clinics, where the patients can be treated in a better way.
Biopharma Sarepta Therapeutics and Brammer Bio enter into a long-term strategic partnership to design and develop new manufacturing facilities at CDMO’s plant in Massachusetts. The new partnership is for the development of the production of its microdystrophin, Duchenne Muscular Dystrophy (DMD) therapy and future gene therapies.
In an innovative push to help biotech start-ups in Britain become independent medium-sized enterprises, the U.K. set up a £2.5 billion patient capital program.
When satellite cells don’t function properly, deterioration of muscles occurs, leading to muscle weakness and fibrosis.
In response to this challenge, an innovative new warning implant system has been developed to detect four common cancers (lung, prostate, breast and colon). The level of calcium in a person’s blood would constantly be checked and if the calcium levels are too high, it warns the patient about the cancer onset by growing an artificial mole on the person’s skin.
The brain is the most difficult part of the body to assess especially the level of signaling molecules called cytokines. Cytokines are secreted by glial cells, which could make up nearly 90% of all brain cells. Cytokines play a key role in controlling moods, cognition and behavior, which directly influences mental health.
Sweden-based Telehealth startup Kry has raised $66 million series B funding round led by Index Ventures, with participation from existing investors Creandum, Accel, and Project A. Just a year ago the company raised its venture capital funding of $22.8 Million
San Francisco based Healthcare venture capital firm Alta Partners has launched funds titled as Alta Partner NextGen Fund I. The new fund will focus on the new development of therapeutics and health technology services. This will be the 9th fund in Alta Partners firms History.
Healthcare industry stakeholders say the FDA should consider a type of measuring stick when evaluating a vendor’s cybersecurity culture to decide whether it meets the requirements for the agency’s proposed fast-past program for premarket approval of "software as a medical device" products (SaMD). Until the end of the last month, the FDA accepted proposals on its working model for a SaMD pre-approval program
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.